Having trouble accessing articles? Reset your cache.

Roche discontinues taspoglutide dosing due to GI events

Roche (SIX:ROG; OTCQX:RHHBY) discontinued dosing of patients in the eight Phase III trials of its T-emerge program of

Read the full 187 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE